TransCode Therapeutics (NASDAQ:RNAZ) Shares Up 0.8% – Still a Buy?

TransCode Therapeutics Inc. (NASDAQ:RNAZ) rose 0.8% during mid-day trading on Wednesday . The stock traded as high as $10.01 and last traded at $9.98. Approximately 14,725 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 617,075 shares. The stock had previously closed at $9.90.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $280.00.

TransCode Therapeutics Stock Up 0.8%

The firm has a market capitalization of $9.18 million, a P/E ratio of -0.37 and a beta of 1.55. The business’s 50-day simple moving average is $8.85 and its 200 day simple moving average is $10.03.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.